Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Mar 06, 2023

SELL
$125.51 - $229.3 $502 - $917
-4 Reduced 0.45%
881 $193,000
Q3 2022

Nov 02, 2022

BUY
$131.8 - $202.24 $8,962 - $13,752
68 Added 8.32%
885 $119,000
Q2 2022

Aug 12, 2022

SELL
$121.11 - $216.05 $22,405 - $39,969
-185 Reduced 18.46%
817 $132,000
Q1 2022

May 13, 2022

BUY
$146.52 - $269.56 $27,545 - $50,677
188 Added 23.1%
1,002 $188,000
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $497 - $778
-2 Reduced 0.25%
814 $220,000
Q3 2021

Nov 12, 2021

SELL
$249.6 - $403.14 $1,248 - $2,015
-5 Reduced 0.61%
816 $296,000
Q2 2021

Aug 10, 2021

BUY
$292.75 - $367.01 $1,756 - $2,202
6 Added 0.74%
821 $281,000
Q1 2021

May 11, 2021

SELL
$260.64 - $382.12 $2,085 - $3,056
-8 Reduced 0.97%
815 $283,000
Q4 2020

Feb 12, 2021

SELL
$221.31 - $316.61 $663 - $949
-3 Reduced 0.36%
823 $212,000
Q3 2020

Nov 13, 2020

SELL
$189.18 - $286.44 $2,648 - $4,010
-14 Reduced 1.67%
826 $236,000
Q2 2020

Aug 12, 2020

SELL
$123.9 - $195.41 $1,982 - $3,126
-16 Reduced 1.87%
840 $158,000
Q1 2020

May 12, 2020

SELL
$121.84 - $173.19 $50,076 - $71,181
-411 Reduced 32.44%
856 $105,000
Q4 2019

Feb 07, 2020

SELL
$115.78 - $208.34 $35,544 - $63,960
-307 Reduced 19.5%
1,267 $210,000
Q3 2019

Nov 12, 2019

SELL
$120.61 - $148.29 $28.3 Million - $34.8 Million
-234,680 Reduced 99.33%
1,574 $193,000
Q2 2019

Aug 09, 2019

SELL
$113.99 - $146.86 $99,171 - $127,768
-870 Reduced 0.37%
236,254 $29.3 Million
Q1 2019

May 10, 2019

BUY
$122.82 - $151.83 $1.04 Million - $1.29 Million
8,478 Added 3.71%
237,124 $31.3 Million
Q4 2018

Feb 12, 2019

BUY
$107.01 - $175.15 $21.9 Million - $35.8 Million
204,621 Added 851.7%
228,646 $32.1 Million
Q3 2018

Nov 02, 2018

BUY
$152.62 - $189.66 $3.53 Million - $4.39 Million
23,148 Added 2639.45%
24,025 $4.14 Million
Q2 2018

Jul 31, 2018

BUY
$152.5 - $216.77 $133,742 - $190,107
877 New
877 $135,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Rockefeller Capital Management L.P. Portfolio

Follow Rockefeller Capital Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.